Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Response Study of E6742 in Systemic Lupus Erythematosus
jRCT2021250057Phase 2Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of e6742 in systemic lupus erythematosus (SLE) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: BICLA response with low-dose oral corticosteroid at Week 24. Started Mar 2026; status: recruiting.
02
Drugs
e6742
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2021250057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250057.